Vice President, Medical and Scientific Affairs, Drug Royalty Corporation

President & COO, Aggregate Therapeutics

Senior Advisor, Life Sciences & Healthcare, MaRS

MaRS Discovery District is a large scale, mission driven innovation centre in Toronto, focused on building Canada's next generation of growth companies. MaRS works closely with entrepreneurs in life sciences and health care, information technology, communications and entertainment, clean tech, advanced materials and energy, as well as the social sector.

MaRS began with a question: “Is there a better way to capture the commercial potential of Toronto’s $1 billion in annual science and technology research spending?”

The answer was a resounding “Yes!”

A charitable organization could be created to better connect the worlds of science, business and government. A public-private partnership with a mission to remove the barriers between silos. Nurture a culture of innovation. And help create global enterprises that would contribute to Canada’s economic and social development.

Visionary individuals and organizations took the lead. They raised capital, secured a strategically-located heritage building and began to develop the MaRS organization.

MaRS provides resources — people, programs, physical facilities, funding and networks — to ensure that critical innovation happens. We stimulate, identify and harness great ideas, nurture their development and guide the transformation of those ideas into reality. We measure our success through the companies that emerge after receiving help from MaRS.

At MaRS, we recognize the value of partnerships. In addition to our core advisory services, MaRS delivers further value to entrepreneurs through five key partners: Business Acceleration Program; MaRS Innovation; Social Innovation Generation; The Ontario Network of Excellence; The Centre for Impact Investing.

MaRS is where science, technology and social entrepreneurs get the help they need. Where all kinds of people meet to spark new ideas. And where a global reputation for innovation is being earned, one success story at a time.

MaRS Discovery District

John has worked for over 25 years building value in the life sciences sector. As the Founder and Managing Director of Burloch Group, John helps connect innovators, developers and financiers to create solutions for unmet medical needs.

Prior to Burloch, John worked with emerging life sciences ventures across Ontario as a Senior Advisor at MaRS.  He founded and managed the highly successful MaRS Future of Medicine™ event series that showcased leading biotech innovators.

John has also served as President and COO of Aggregate Therapeutics Inc - a Canadian stem cell "mutual fund" and from 1994 to 2006 he worked for Drug Royalty Corporation Inc (now DRI Capital) where he served as Vice President, Medical & Scientific Affairs.  He completed 20 investments (totaling $250 million) with excellent returns and subsequently assisted in a $300 million investment as an independent advisor.

John holds a PhD in immunology from the University of London and is a graduate of the Canadian Securities Course.

Biotechnology

Pharmaceuticals

Innovation

Investment

Burloch Group Inc.

MaRS Blogs

Stem cell commercialization – the Canadian experience

Commercializing Life Sciences in the UK

Building great companies from Canadian technology

Find out the common mistakes biotech start-ups make and, more importantly, how to avoid them.

Top 10 Mistakes to Avoid for Biotech Entrepreneurs

Founder & Managing Director

Interested in rubbing elbows with some of Toronto's hottest life sciences start-ups? Come hear successful entrepreneurs discuss the challenges and opportunities faced in launching their organizations. Moderated by John McCulloch, this life sciences panel will include: Paul Chipperton, CEO, Profound Medical Inc. Profound Medical Inc. is commercializing a minimally-invasive medical device that has the potential to transform prostate cancer treatment. The privately-owned company is preparing for clinical trials in Canada, EU and the US. Greg Hines, CEO, ArcticDx Inc. ArcticDx Inc. specializes in diagnostic tests. Its lead product, Macula Risk, identifies those who may lose their sight due to macular degeneration—leading to better management of the disease to prevent blindness. Dr. Steve Herman, President, MedCurrent MedCurrent develops decision support systems for the health-care sector. Their product, OrderRight™, guides physicians to the best test to order for their patients, helping alleviate the enormous costs of inappropriate medical imaging procedures. This is part of a series of "Meet the Entrepreneurs" events which present panels of start-up entrepreneurs in different sectors discussing the challenges and opportunities they are facing. MaRS - Building Canada's next generation of global technology companies. marsdd.com

Entrepreneurship 101 2010/11 - Meet the Entrepreneurs - Life Sciences & Health Care

After last year's successful inaugural session, the MaRS Future of Medicine™ Conference returns for its second year! With a lineup of great speakers focusing on two emerging themes in medicine, this year's conference will both enlighten and inspire. Conference highlights include: Breakthrough medical innovations Exciting new approaches to drug discovery Innovative paths in personalized medicine Ontario's response to the challenge of infectious disease How to expand your business with the MaRS Future of Medicine™ partnering forum The opportunity to meet decision makers from pharma, biotech and venture capital

MaRS Future of Medicine 2010 Conference Promo

Increasing costs and decreased productivity have hampered growth and investment in the global life sciences and health-care sector. The open-innovation approach embraced by many industries could transform the way biotech and health-care companies innovate—bringing products and services to market quickly and efficiently. What does this mean for business and consumers in Ontario? Presenting diverse perspectives, this breakfast panel will examine the open-innovation approach and identify opportunities and challenges for health-care stakeholders as they position themselves in the value chain. Learn how to use this approach and leverage it with success. Moderator: John McCulloch, Senior Advisor, Life Sciences and Health Care, MaRS Panelists: Mark Lundie, Director of R&D, Pfizer Michael May, CEO, The Centre for Commercialization Niall Wallace, CEO, Infonaut Inc Aled Edwards, Director and CEO, Structural Genomics Consortium MaRS - Building Canada's next generation of global technology companies. marsdd.com

John McCulloch

MaRS Discovery District

Media

Social

Biography

Industry Expertise

Areas of Expertise

Accomplishments

Vice President, Medical and Scientific Affairs, Drug Royalty Corporation

President & COO, Aggregate Therapeutics

Senior Advisor, Life Sciences & Healthcare, MaRS

Education

University of London

University of Glasgow

Canadian Securities Institute

Links

Event Appearances

Stem cell commercialization – the Canadian experience

Commercializing Life Sciences in the UK

Building great companies from Canadian technology

Sample Talks

Top 10 Mistakes to Avoid for Biotech Entrepreneurs

Style

Availability

Fees